Oncternal Therapeutics
1042-B North El Camino Real
Encinitas, CA 92024
Encinitas, CA 92024
Encinitas, CA 92024
United States
Tel: 858-434-1113
Fax: 858-408-3010
Website: http://www.oncternal.com/
Email: info@oncternal.com
152 articles about Oncternal Therapeutics
-
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - June 01, 2021
6/1/2021
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that it has granted an inducement award to one new employee, Christopher Markey, who joined the company as Director, Program and Alliance Management.
-
Oncternal Therapeutics to Participate in Jefferies Virtual Healthcare Conference - May 26, 2021
5/26/2021
Oncternal Therapeutics, a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that management will present a corporate overview at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 10:30 am Eastern Time.
-
Oncternal Therapeutics Presents Updated Interim Data for TK216 in Patients with Relapsed or Refractory Ewing Sarcoma in an Oral Session at ASCO 2021
5/19/2021
Latest data from study TK216-01 remain encouraging, are consistent with previous results, and are updated over data contained in ASCO Abstract #11500 released today Two patients who achieved a complete response (CR) remain with no evidence of disease, one for over 24 months and the other for over 14 months on study TK216 remained generally well tolerated with a manageable safety profile
-
Oncternal Therapeutics Presents Updated Interim Data for Cirmtuzumab in Combination with Ibrutinib at ASCO 2021
5/19/2021
Latest data from the CIRLL study to be presented at ASCO 2021 remain encouraging, demonstrate good, continued enrollment, are consistent with previous results and are updated over data contained in abstract #7556 released today
-
Oncternal Therapeutics Announces Appointment of Salim Yazji as Chief Medical Officer
5/17/2021
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of industry veteran Salim Yazji, M.D., as Chief Medical Officer.
-
Oncternal Provides Business Update and Announces First Quarter 2021 Financial Results
5/6/2021
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, reported financial results for the first quarter of 2021.
-
Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - May 03, 2021
5/3/2021
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that it has granted inducement awards to two new non-executive employees.
-
Oncternal Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update
4/29/2021
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that it will report first quarter 2021 financial results after the U.S. financial markets close on Thursday, May 6, 2021.
-
Oncternal Therapeutics Announces Presentation of Two Abstracts at ASCO 2021 Virtual Meeting
4/28/2021
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the presentation of two abstracts at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting being held virtually from June 4-8, 2021.
-
Oncternal Therapeutics Announces Presentation of Three Posters at AACR 2021 Virtual Meeting
4/12/2021
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the presentation of three posters at the American Association for Cancer Research (AACR) 2021 Annual Meeting being held virtually from April 10-15, 2021.
-
Oncternal Therapeutics Announces Appointment of Chase Leavitt as General Counsel
4/12/2021
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Chase Leavitt as General Counsel. Mr. Leavitt joins the Company with extensive experience providing strategic, transactional, financial, and operational advice to life sciences companies.
-
Oncternal Therapeutics Reports Granting of an Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - Mar 18, 2021
3/18/2021
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that it has granted an inducement award to one new employee, Anita Wiseth, who joined the company as Senior Vice President, Human Resources.
-
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2020 Financial Results
3/11/2021
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported fourth quarter and full year 2020 financial results.
-
Oncternal Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Business Update
3/4/2021
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report fourth quarter and full year 2020 financial results after the U.S. financial markets close on Thursday, March 11, 2021.
-
Oncternal Therapeutics to Participate in March Investor Conferences
2/24/2021
- H.C. Wainwright: Global Life Sciences Conference - March 9 th – 10 th - Oppenheimer 31 st Annual Healthcare Conference - March 16 th – 17 th
-
Oncternal Therapeutics Reports Granting of an Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2/22/2021
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted an inducement award to one new non-executive employee, Christy Stolzer, who joined the company as Associate Director, Drug Safety.
-
Oncternal Therapeutics Announces the Appointment of Dr. Rosemary Mazanet to the Board of Directors
1/28/2021
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Rosemary Mazanet, M.D., Ph.D., to its Board of Directors, effective January 27, 2021. Dr. Mazanet has extensive experience in all stages of oncology drug development from investigational new drug submission (“IND”) through new drug application (“NDA”) approval and commercia
-
Oncternal Therapeutics, Inc. Confirms Lentigen Technology, Inc. to Manufacture Lentiviral Vectors for Its ROR1-targeting CAR-T Cell Therapy Program
1/14/2021
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced an agreement with Lentigen Technology, Inc. (“Lentigen”), a wholly-owned subsidiary of Miltenyi Biotec B.V. & Co. KG, to manufacture lentiviral vectors for Oncternal’s investigational ROR1-targeting CAR-T cell therapy program.
-
Oncternal Therapeutics and Karolinska Institutet Establish Collaboration for Research and Development of ROR1-targeting CAR-T and CAR-NK Cell Therapies
1/7/2021
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it established a research and development collaboration with world-renowned Karolinska Institutet in Stockholm, Sweden, to advance novel ROR1-targeting cell therapies focused on CAR-T cells and CAR-NK (Natural Killer) cells from the laboratory into the clinic. As
-
Oncternal Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect 2021 Conference
1/5/2021
Oncternal Therapeutics (Nasdaq: ONCT), today announced that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat hosted by H.C. Wainwright on Monday, January 11, 2021. The discussion may cover Oncternal’s recent progress, upcoming catalysts, and plans for 2021. Please see additional details below: H.C. Wainwright BioConnect 2021 Conference (Virtual) Title: On